Prof. Dr. Andreas Pahl, CSO, Heidelberg Pharma
Download the presentation slides
The human TNFα mouse is genetically modified mouse that overexpresses human TNFα and spontaneously develops arthritis without any experimental manipulation.
Data from two independent studies at different locations and validation with biological standard of care therapeutics were presented.
Experimental considerations and recommendations were discussed.
More about Prof. Dr. Andreas Pahl
Professor Pahl has 20 years experience in research and teaching and excellent expertise in pharmacology, toxicology, and pharmacokinetics.
In 2008, he joined industry to pursue drug development for inflammatory and autoimmune diseases at Nycomed and Takeda.
In 2012 he joined Heidelberg Pharma as the CSO extending his expertise to the area of oncology and antibody-drug conjugates.
Professor Pahl continues to be adjunct Professor for pharmacology and toxicology at the University of Erlangen-Nuremberg.
About Heidelberg Pharma
Heidelberg Pharma AG is a pharmaceutical company with a dual business model: (A)
Providing preclinical drug development services.
As a preclinical CRO Heidelberg Pharma offers explorative pharmacology, drug metabolism, and pharmacokinetics (DMPK) analysis and molecular biology.
Its core competence is the preclinical profiling of small molecules or biologicals destined for the treatment of cancer or inflammatory/autoimmune diseases.
Development of novel therapeutics in oncology.
Heidelberg Pharma's own R&D flagship is its proprietary 2nd generation antibody-drug-conjugate (ADC) technology for more effective and specific anti-cancer drugs.